$19.27
6.73% today
Nasdaq, Feb 05, 04:19 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$18.05
-1.86 9.34% 1M
-6.87 27.57% 6M
-1.12 5.84% YTD
-28.25 61.02% 1Y
-51.30 73.97% 3Y
-31.92 63.88% 5Y
+2.00 12.46% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.95 5.56%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Market capitalization $1.24b
Enterprise Value $120.17m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 0.75
P/S ratio (TTM) P/S ratio 7.70
P/B ratio (TTM) P/B ratio 2.12
Revenue growth (TTM) Revenue growth 0.94%
Revenue (TTM) Revenue $161.10m
EBIT (operating result TTM) EBIT $-357.40m
Cash position $1.12b
EPS (TTM) EPS $-4.67
P/E forward negative
P/S forward 4.69
EV/Sales forward 0.45
Short interest 14.47%
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Arvinas, Inc. forecast:

20x Buy
91%
2x Hold
9%

Analyst Opinions

22 Analysts have issued a Arvinas, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
161 161
1% 1%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 153 153
107% 107%
95%
- Research and Development Expense 360 360
6% 6%
224%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -357 -357
15% 15%
-222%
Net Profit -309 -309
4% 4%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET.
Positive
The Motley Fool
15 days ago
Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopharmaceutical industry are poised to soar by the end of March.
Neutral
GlobeNewsWire
26 days ago
– Vepdegestrant to be combined with Pfizer's novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will combine vepdegestrant with a CDK4/6 inhibitor, also planned to initiate in 2025 –
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 445
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today